GeoVax Labs, Inc. (Nasdaq: GOVX), a leader in developing immunotherapies and vaccines for cancers and infectious diseases, is set to disclose its third quarter 2024 financial results on November 12, 2024, after the U.S. markets close. A subsequent conference call and webcast at 4:30 p.m. ET will offer a corporate update and financial discussion, accessible via registration or through the company's website.
The announcement is timely, as GeoVax advances its clinical programs, notably the GEO-CM04S1 COVID-19 vaccine. A BARDA-funded contract supports a Phase 2b trial with 10,000 participants, comparing GEO-CM04S1's effectiveness against an approved vaccine. This trial, among others, could significantly impact global public health by offering new prevention options, especially for immunocompromised individuals and those seeking durable boosters.
In oncology, GeoVax's Gedeptin® shows promise for treating advanced head and neck cancers, with a Phase 2 trial planned for 2025. This trial explores Gedeptin® combined with an immune checkpoint inhibitor, potentially revolutionizing cancer treatment approaches.
GeoVax's upcoming financial and corporate updates are crucial for investors and the medical community, reflecting the company's role in addressing pressing health challenges. The developments in vaccine and cancer therapy research align with global health priorities, making this announcement significant for stakeholders and public health initiatives worldwide.
For detailed insights, the webcast will be archived on GeoVax's website for 90 days, ensuring stakeholders can thoroughly assess the company's progress and future directions.
